

# GenesWell BCT Oncotype DX

SEOUL, SOUTH KOREA, April 30, 2025  
 /EINPresswire.com/ --  
 GENCURIX  
 GenesWell BCT  
 Oncotype  
 DX (21)

50  
 HER  
 2  
 HR+/HER2-  
 759  
 20  
 19  
 2023  
 ASCO

Frontiers in  
 Oncology  
 GenesWell  
 BCT  
 Oncotype  
 DX  
 RFS

GenesWell  
 BCT  
 7  
 RF  
 S  
 95.0%  
 88.4%  
 Oncotype  
 DX  
 93.7%  
 88.1%

HR  
 GenesWell  
 BCT  
 2.469  
 95%  
 1.446–4.214  
 Oncotype DX  
 2.093  
 95%  
 1.138–3.850

Oncotype DX  
 RS  $\leq 25$   
 GenesWell  
 BCT  
 RFS  
 HR=2.477

Oncotype DX  
 RS 16–25  
 50  
 209  
 GenesWell



Gencurix CI

Geneswell BCT

BCTPMSMFDSRFS  
P=0.007  
P=0.020

Sung Gwe  
Ahn7  
Oncotype  
DX

Sae Byul  
Lee

GenesWell  
BCTMFDS60010  
PMS

Sang Uk Woo  
BCT

GenesWell  
BCT

Gencurix  
Gencurix  
[email us here](#)

